Stock Track | Biostar Pharmaceuticals Soars 30% Following Successful $16 IPO Pricing

Stock Track10-31

Shares of Beijing Biostar Pharmaceuticals Co Ltd surged 30% on Wednesday, the first trading day after the company announced the final offer price of HK$16.00 (approx. $2.04) per share in its global initial public offering (IPO).

The significant stock price increase reflects strong investor demand for the Chinese biopharmaceutical firm's shares. Biostar Pharmaceuticals raised around $344 million in the Hong Kong IPO, according to Reuters calculations based on the final pricing.

Founded in 2020, Biostar Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for metabolic diseases, oncology, and other areas with high unmet medical needs. The company plans to use the IPO proceeds to fund clinical trials, research and development activities, and potential commercialization of its drug candidates.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146934064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146934064","market":"us","top_or_hot":-1,"title":"Stock Track | Biostar Pharmaceuticals Soars 30% Following Successful $16 IPO Pricing","media":"Stock Track","content":"<p>Shares of Beijing Biostar Pharmaceuticals Co Ltd surged 30% on Wednesday, the first trading day after the company announced the final offer price of HK$16.00 (approx. $2.04) per share in its global initial public offering (IPO).</p>\n\n<p>The significant stock price increase reflects strong investor demand for the Chinese biopharmaceutical firm's shares. Biostar Pharmaceuticals raised around $344 million in the Hong Kong IPO, according to Reuters calculations based on the final pricing.</p>\n\n<p>Founded in 2020, Biostar Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for metabolic diseases, oncology, and other areas with high unmet medical needs. The company plans to use the IPO proceeds to fund clinical trials, research and development activities, and potential commercialization of its drug candidates.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Biostar Pharmaceuticals Soars 30% Following Successful $16 IPO Pricing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Biostar Pharmaceuticals Soars 30% Following Successful $16 IPO Pricing\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-31 09:33 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Beijing Biostar Pharmaceuticals Co Ltd surged 30% on Wednesday, the first trading day after the company announced the final offer price of HK$16.00 (approx. $2.04) per share in its global ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"华昊中天医药-B","start_time":0,"source_url":"","article_id":"1146934064","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146934064","pubTimestamp":1730338404,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Beijing Biostar Pharmaceuticals Co Ltd surged 30% on Wednesday, the first trading day after the company announced the final offer price of HK$16.00  per share in its global initial public offering .The significant stock price increase reflects strong investor demand for the Chinese biopharmaceutical firm's shares. Biostar Pharmaceuticals raised around $344 million in the Hong Kong IPO, according to Reuters calculations based on the final pricing.Founded in 2020, Biostar Pharmaceuticals","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"Biostar Pharmaceuticals成功IPO定价16美元后股价飙升30%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Shares of Beijing Biostar Pharmaceuticals Co Ltd surged 30% on Wednesday, the first trading day after the company announced the final offer price of HK$16.00 (approx. $2.04) per share in its global initial public offering (IPO).\nThe significant stock price increase reflects strong investor demand for the Chinese biopharmaceutical firm's shares. Biostar Pharmaceuticals raised around $344 million in the Hong Kong IPO, according to Reuters calculations based on the final pricing.\nFounded in 2020, Biostar Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for metabolic diseases, oncology, and other areas with high unmet medical needs. The company plans to use the IPO proceeds to fund clinical trials, research and development activities, and potential commercialization of its drug candidates.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146934064"}